APA (7th ed.) Citation

CJ, S., B, K., A, G., HB, N., AB, K., CC, Z., . . . FG, B. (2026). Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension. Journal of the American Academy of Dermatology, 94(3), 867. https://doi.org/10.1016/j.jaad.2025.11.031

Chicago Style (17th ed.) Citation

CJ, Sayed, et al. "Bimekizumab Demonstrated a Favorable Safety Profile and High Levels of Efficacy with Up to 2 Years of Treatment in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled Results from Two Phase 3 Randomized, Controlled Trials and Their Open-label Extension." Journal of the American Academy of Dermatology 94, no. 3 (2026): 867. https://doi.org/10.1016/j.jaad.2025.11.031.

MLA (9th ed.) Citation

CJ, Sayed, et al. "Bimekizumab Demonstrated a Favorable Safety Profile and High Levels of Efficacy with Up to 2 Years of Treatment in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled Results from Two Phase 3 Randomized, Controlled Trials and Their Open-label Extension." Journal of the American Academy of Dermatology, vol. 94, no. 3, 2026, p. 867, https://doi.org/10.1016/j.jaad.2025.11.031.